

# financial statements unaudited

---

## **Blackrock Pharmaceuticals Limited**

For the period ended 31 December 2009

Company registration number 6458588

WEDNESDAY



\*A2BKYNTL\*

A14

29/09/2010

20

COMPANIES HOUSE

# Blackrock Pharmaceuticals Limited

---

## Directors' Report

The directors present their annual report together with the unaudited financial statements of the company for the year ended 31 December 2009

### PRINCIPAL ACTIVITY

The company supplies a broad range of pharmaceutical medicines to the healthcare industries

### DIRECTORS

The directors who served the company during the year were as follows

Ms Una Loughrey  
Mr Peter Griffin  
Mr Desmond McMahon  
Mr Philip McFerran  
Ms Judith Ball

### RESPONSIBILITIES OF THE DIRECTORS

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). The financial statements are required by law to give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to


- select suitable accounting policies and then apply them consistently,
- make judgements and estimates that are reasonable and prudent,
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and which enable them to ensure that the financial statements comply with Companies Act 2006. The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Small company provisions

This report has been prepared in accordance with the provisions applicable to the small companies regime.

Signed by order of the directors



Ms Judith Ball  
Company Secretary  
27 September 2010

# Blackrock Pharmaceuticals Limited

## Balance Sheet

31 December 2009

	Note	As at 31 December 2009	As at 31 December 2008
<b>Current assets</b>			
Debtors	2	4,890	2,090
Cash at bank		<u>12,913</u>	<u>30,221</u>
		17,803	32,311
<b>Creditors' amounts falling due within one year</b>	3	(146,174)	(79,087)
<b>Total assets less current liabilities</b>		<u>(128,371)</u>	<u>(46,776)</u>
<b>Net liabilities</b>		<u>£(128,371)</u>	<u>£(46,776)</u>
<b>Capital and reserves</b>			
Called up share capital	4	90	90
Profit and loss account		<u>(128,461)</u>	<u>(46,866)</u>
<b>Total funds</b>		<u>£(128,371)</u>	<u>£(46,776)</u>


For the year ending 31 December 2009 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies

### Directors responsibilities,

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts

These accounts have been prepared in accordance with the provision applicable to companies subject to the small companies regime

The financial statements were approved and authorised for issue by the Directors on 27 September 2010, and signed on their behalf by



Mr P Griffin  
Director

The notes on pages 4 to 5 form part of these financial statements

# Blackrock Pharmaceuticals Limited

## Notes to the Financial Statements

Year ended 31 December 2009

---

### 1. Accounting policies

#### Basis of accounting

The financial statements have been prepared under the historical cost convention

#### Cash flow statement

The directors have taken advantage of the exemption in Financial Reporting Standard No 1 (revised) from including a cash flow statement in the financial statements on the grounds that the company is small

### 2. Debtors

	31 Dec 2009	31 Dec 2008
	£	£
Trade debtors	4,800	2,000
Called up share capital not paid	90	90
	<u>4,890</u>	<u>2,090</u>

### 3 Creditors. Amounts falling due within one year

	31 Dec 2009	31 Dec 2008
	£	£
Other creditors due to Pharmalink Consulting Limited	146,174	79,087
	<u>146,174</u>	<u>79,087</u>

# Blackrock Pharmaceuticals Limited

## Notes to the Financial Statements

Year ended 31 December 2009

---

### 4. Share Capital

	Authorised 2009 No	Allotted and called up 2009 £
Ordinary shares of £1 each	<u>100</u>	<u>90</u>

The amounts of paid up share capital for the following categories of shares differed from the called up share capital stated above due to unpaid calls and were as follows

	2009 £
Ordinary shares of £1 each	<u>90</u>

### 5. Related party transactions

Mr Peter Griffin is a director and joint majority shareholder with Ms Una Loughrey, of Pharmalink Consulting Limited £146,174 is due to Pharmalink Consulting Limited at the year end